DarioHealth (NASDAQ:DRIO) Upgraded by Alliance Global Partners to Buy

DarioHealth (NASDAQ:DRIO – Get Rating) was upgraded by equities research analysts at Alliance Global Partners from a “neutral” rating to a “buy” rating in a note issued to investors on Friday, The Fly reports.

Several other brokerages also recently issued reports on DRIO. Cowen reduced their price objective on DarioHealth from $30.00 to $14.00 in a research report on Monday, April 18th. Cowen cut their price objective on DarioHealth from $30.00 to $14.00 in a report on Monday, April 18th. Finally, Aegis lowered their target price on DarioHealth from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, January 26th. Four equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $17.90.

DarioHealth stock opened at $5.18 on Friday. The firm has a market capitalization of $113.03 million, a price-to-earnings ratio of -1.24 and a beta of 1.36. DarioHealth has a fifty-two week low of $4.11 and a fifty-two week high of $23.80. The stock’s fifty day moving average is $5.84 and its two-hundred day moving average is $10.12.

DarioHealth (NASDAQ:DRIO – Get Rating) last posted its earnings results on Tuesday, March 22nd. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.04. The company had revenue of $6.03 million for the quarter, compared to analyst estimates of $6.24 million. DarioHealth had a negative return on equity of 73.04% and a negative net margin of 374.21%. During the same quarter in the prior year, the company earned ($1.06) earnings per share. On average, equities research analysts anticipate that DarioHealth will post -3.17 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of DRIO. Steward Partners Investment Advisory LLC purchased a new position in shares of DarioHealth during the first quarter valued at $25,000. UBS Group AG boosted its position in DarioHealth by 706.5% during the third quarter. UBS Group AG now owns 4,250 shares of the company’s stock valued at $58,000 after purchasing an additional 3,723 shares during the last quarter. Morgan Stanley lifted its position in shares of DarioHealth by 219.2% in the first quarter. Morgan Stanley now owns 3,543 shares of the company’s stock worth $68,000 after buying an additional 2,433 shares during the last quarter. Focused Wealth Management Inc lifted its position in shares of DarioHealth by 150,000.0% in the fourth quarter. Focused Wealth Management Inc now owns 6,004 shares of the company’s stock worth $78,000 after buying an additional 6,000 shares during the last quarter. Finally, Klingman & Associates LLC acquired a new stake in shares of DarioHealth in the first quarter worth about $86,000. Institutional investors and hedge funds own 49.01% of the company’s stock.

DarioHealth Company Profile (Get Rating)

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems.

Read More